Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-344

Yes, SI explains on the webcast why they still see no reduction in non-fatal events, but much better mortality rates. He puts it down to the anti-inflammatory and regenerative effects of the stem cell treatment. The original cardiac irregularities that cause events are still there, but essentially the heart is stronger due to treatment and therefore more able to cope with these events, which are therefore not mortal in effect. Basically the treatment reverses the build up of scar tissue seen otherwise, effectively reversing necrosis in the heart, for a stronger like for like heart function.

Combine this treatment with something that also reduces the patients propensity to events, if not overall mortality, and patients are going to have an extra 3-5 years on this earth through the two. I wish the written release was more along the lines of the webcast. They are chalk and cheese. SI is very matter of fact, not talking it up, but if the FDA/partner discussions are anything like the webcast, this treatment should and will be available to chronic heart failure patients.